Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assembly Biosciences (ASMB)
NASDAQ:ASMB
RESEARCH TOOLSreports
Holding ASMB?
Track your performance easily
ASMB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.69 - $19.93
Previous Close$15.02
Volume63.87K
Average Volume (3M)29.35K
Market Cap
$97.51M
Enterprise Value$3.99M
Total Cash (Recent Filing)$94.95M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Mar 06, 2025EPS Estimate
-$1.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.14
Shares Outstanding6,356,286
10 Day Avg. Volume25,463
30 Day Avg. Volume29,352
Standard Deviation0.17
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.67
Price to Sales (P/S)3.44
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.19
Enterprise Value/Gross Profit0.56
Enterprise Value/Ebitda-0.08
Forecast
1Y Price Target
$35.50Price Target Upside141.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Assembly Biosciences News
PremiumCompany Announcements
Assembly Biosciences Reports Q3 2024 Financials and Strategic Advances
PremiumPre-Earnings
Is ASMB a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNew financing extends cash runway into the first quarter of 2026.
Market PotentialThe HSV market, including recurrent cases, seems solid and could potentially be worth over $1 billion.
Product DevelopmentABI-5366 could potentially offer a longer-acting option for HSV treatment, making it more convenient and potentially better in terms of efficacy.
Bears Say
Clinical TrialsUncertainty on the safety and efficacy of Assembly's programs including ABI-5366 and ABI-6250.
Financial RisksKey risks include failed or equivocal trial results, unforeseen safety or tolerability issues, meaningful delays to expected timelines, and inability to sufficiently fund operations.
Product EfficacyWhat remains to be seen is its antiviral activity in Part B of the study.
---
Ownership Overview
33.08% Insiders
6.04% Mutual Funds
6.78% Other Institutional Investors
50.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $7.69 and its highest was $19.93 in the past 12 months.
What is Assembly Biosciences’s market cap?
Currently, no data Available
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Mar 06, 2025 which is in 104 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Nov 07, 2024. The company reported -$1.51 earnings per share for the quarter, beating the consensus estimate of -$2.303 by $0.793.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -$1.97.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 6,356,286 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$1.51 in its last earnings report, beating expectations of -$2.303. Following the earnings report the stock price went down -4.114%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Among the largest hedge funds holding Assembly Biosciences’s share is Platinum Investment Management. It holds Assembly Biosciences’s shares valued at N/A.
---
Assembly Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.50 (141.17% Upside)
$35.50 (141.17% Upside)
Hedge Fund Trend
Decreased
By 74.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $139.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.53%
12-Months-Change
Fundamentals
Return on Equity
-120.51%
Trailing 12-Months
Asset Growth
94.20%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
---
ASMB Stock 12 Month Forecast
Average Price Target
$35.50
▲(141.17% Upside)
Technical Analysis
Moleculin Biotech
―
Aurinia Pharmaceuticals
―
Viking Therapeutics
―
Kezar Life Sciences
―
Best Analysts Covering ASMB
1 Year
1 Year Success Rate
4/28 ratings generated profit
1 Year Average Return
-40.31%
assigned a buy rating 2 months ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -40.31% per trade.
---